Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03789253

Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer

Sponsor: National Taiwan University Hospital

View on ClinicalTrials.gov

Summary

In Taiwan, about 70% of new incident prostate cancer patients have localized disease. Most patients were detected by PSA screening. Among them, many had low-risk PC, which is very likely latent in nature, progresses slowly, and rarely leads to death. Most patients died of other causes, such as other cancers, cardiovascular diseases, and diabetes mellitus. Many guidelines recommend that active surveillance (AS) or watchful waiting (WW) is a good option for low risk patients to avoid overtreatment-related complications. However, 30% of patients on AS will finally need definitive treatments due to disease progression within 10 years. We hypothesize that there are differential gene expressions between progressive and non-progressive tumors. If we can identify key genes or pathways that are responsible for progression of low risk PC to higher risk diseases, PC progression could be reduced substantially by regulating these genes or pathways and maintain long-term cancer latency to control non-metastatic PC. In light of the high prevalence rate of latent PC in adult men, the strategy is in fact the best strategy for preventing clinical PC.

Official title: Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer-A New Strategy for Prostate Cancer Prevention

Key Details

Gender

MALE

Age Range

40 Years - 100 Years

Study Type

OBSERVATIONAL

Enrollment

300

Start Date

2019-01-02

Completion Date

2030-07-31

Last Updated

2022-08-12

Healthy Volunteers

No

Locations (1)

National Taiwan University

Taipei, Taiwan